Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
3 Pharmaceutical Stocks With Awesome Futures
11:15am, Saturday, 09'th Apr 2022 The Motley Fool
The market is so pessimistic about anything COVID-related that everything has gotten super cheap.
3 Things About Pfizer That Smart Investors Know
03:07pm, Friday, 08'th Apr 2022 The Motley Fool
The next few years might get a little bumpy.
Antibody Treatments for COVD-19 Face Challenges in the U.S.
01:31pm, Friday, 08'th Apr 2022 Zacks Investment Research
With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a
GlaxoSmithKline (GSK) Outpaces Stock Market Gains: What You Should Know
09:50pm, Thursday, 07'th Apr 2022 Zacks Investment Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $46.23, marking a +1.12% move from the previous day.
BA.2 subvariant of omicron accounted for almost 94% of global cases in latest week, the latest sign of how dominant it has become
11:57am, Thursday, 07'th Apr 2022 MarketWatch
The omicron variant of the coronavirus that causes COVID-19 accounted for 99.8% of global new cases in the latest week, the World Health Organization said Wednesday, and the BA.2 subvariant accounted
VIR Stock Down on Another Setback for COVID-19 Antibody
04:25pm, Wednesday, 06'th Apr 2022 Zacks Investment Research
VIR and partner Glaxo suffer a setback as the FDA determines that sotrovimab is no longer authorized for use in the United States for COVID-19.
3 CEOs to Invest In
01:00am, Saturday, 02'nd Apr 2022 The Motley Fool
Looking for a healthcare stock with strong leadership? Our roundtable likes Immunocore, Axsome Therapeutics, and GlaxoSmithKline.
Why Shares of Vir Biotechnology Rose 20.4% This Week
04:43pm, Friday, 01'st Apr 2022 The Motley Fool
Joining the S&P SmallCap 600 could boost the company's profile.
Pharma Stock Roundup: FDA Nod for 2nd COVID Booster, New Approvals for AZN, GSK, NVS
01:09pm, Friday, 01'st Apr 2022 Zacks Investment Research
FDA authorizes second booster dose of PFE and MRNA COVID-19 vaccines for older adults. RHHBY's late-stage study for ES-SCLC fails.
GlaxoSmithKline (GSK) Stock Moves -0.32%: What You Should Know
09:45pm, Thursday, 31'st Mar 2022 Zacks Investment Research
GlaxoSmithKline (GSK) closed the most recent trading day at $43.56, moving -0.32% from the previous trading session.
Adagio's (ADGI) COVID-19 Antibody Meets Goals in Studies
04:14pm, Thursday, 31'st Mar 2022 Zacks Investment Research
The stock price of Adagio (ADGI) surge after it reports positive preliminary data from the phase II/III studies, which evaluate its monoclonal antibody for the prevention and treatment of COVID-19.
VIR Stock Gains on News of Inclusion in the S&P SmallCap 600
03:23pm, Thursday, 31'st Mar 2022 Zacks Investment Research
Vir Biotechnology (VIR) shares gain as the company is set to join the S&P SmallCap 600 effective prior to the opening of trading on Monday, Apr 4.
WHO urges countries to keep up COVID-19 testing and surveillance as the viral outbreak remains a global pandemic
12:07pm, Thursday, 31'st Mar 2022 MarketWatch
The World Health Organization said Wednesday it's increasingly concerned at the reduction in COVID-19 testing, surveillance and overall monitoring among its member countries, reminding the public that
J&J (JNJ) Gets FDA Nod for HIV Jab, Cabenuva, in Adolescents
04:28pm, Wednesday, 30'th Mar 2022 Zacks Investment Research
The FDA approves Johnson & Johnson's (JNJ) Cabenuva for treating HIV-1 in virologically suppressed adolescents aged 12 years and above.
AstraZeneca (AZN) Gets EU Nod for COVID-19 Antibody Cocktail
04:31pm, Monday, 28'th Mar 2022 Zacks Investment Research
The European Commission approves AstraZeneca's (AZN) Evusheld for the pre-exposure prophylaxis of COVID-19 infection in a broad patient population.
